Last updated: April 7, 2022
Sponsor: Zhongnan Hospital
Overall Status: Active - Recruiting
Phase
2
Condition
Peritoneal Cancer
Treatment
N/AClinical Study ID
NCT05325554
HCCSC AB05
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who are diagnosed as abdominal malignant tumor by pathology and / or cytologyand intend to receive concurrent radiotherapy and chemotherapy;
- Estimated survival time ≥ 3 months;
- ECoG score 0-1;
- The physical activity is acceptable, and the human body composition analysis and 6-minute walking test can be carried out;
- Have reading comprehension ability and be able to complete the questionnaire.
Exclusion
Exclusion Criteria:
- Clinically significant cardiovascular diseases, such as heart failure (NYHA gradeIII-IV), uncontrolled coronary heart disease, cardiomyopathy, uncontrolled arrhythmia,uncontrolled hypertension or history of myocardial infarction in the past 1 year;
- Neurological or psychiatric abnormalities affecting cognitive ability, includingcentral nervous system metastasis;
- uncontrolled systemic diseases, such as poorly controlled diabetes mellitus;
- Allergic to milk, whey protein, etc.
Study Design
Total Participants: 100
Study Start date:
February 07, 2022
Estimated Completion Date:
January 31, 2024
Study Description
Connect with a study center
Zhongnan Hopital of Wuhan University
Wuhan, Hubei 430070
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.